Role of IGF-1 in age-related loss of skeletal muscle mass and function

5Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.
Get full text

Abstract

While insulin-like growth factor-1 (IGF-1) is closely involved in the growth, hypertrophy and maintenance of skeletal muscle mass, the role of IGF-1 in age-related muscle wasting (sarcopenia) is unclear: this is the focus of the present discussion. The complexity of the IGF-1 system that involves different IGF-1 isoforms, binding proteins and receptors, with modulation of systemic IGF-1 levels by growth hormone (GH) is first outlined. The classic IGF-1 signalling pathways in skeletal muscle with a focus on the central role of Akt in protein synthesis and degradation are presented and various conditions that can impair IGF-1 signalling are discussed with respect to inflammation (TNF), oxidative stress (ROS) and lipids. Complex interactions between other factors that influence the age-related decrease in IGF-1 activity are addressed, including GH, nutrition, caloric restriction, Klotho and Vitamin D. Finally, the potential for therapeutic interventions for sarcopenia related to IGF-1 signalling is considered. The big questions are 'to what extent does IGF-1 contribute to sarcopenia' and 'can elevated IGF-1 prevent or reverse sarcopenia?

Cite

CITATION STYLE

APA

McMahon, C. D., Shavlakadze, T., & Grounds, M. D. (2011). Role of IGF-1 in age-related loss of skeletal muscle mass and function. In Sarcopenia - Age-Related Muscle Wasting and Weakness: Mechanisms and Treatments (pp. 393–418). Springer Netherlands. https://doi.org/10.1007/978-90-481-9713-2_17

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free